In last trading session, Tscan Therapeutics Inc (NASDAQ:TCRX) saw 0.58 million shares changing hands with its beta currently measuring 0.96. Company’s recent per share price level of $1.74 trading at -$0.05 or -2.79% at ring of the bell on the day assigns it a market valuation of $98.47M. That closing price of TCRX’s stock is at a discount of -456.9% from its 52-week high price of $9.69 and is indicating a premium of 1.72% from its 52-week low price of $1.71. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.33 million shares which gives us an average trading volume of 413.38K if we extend that period to 3-months.
For Tscan Therapeutics Inc (TCRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.12. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Tscan Therapeutics Inc (NASDAQ:TCRX) trade information
Upright in the red during last session for losing -2.79%, in the last five days TCRX remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $1.74 price level, adding 11.68% to its value on the day. Tscan Therapeutics Inc’s shares saw a change of -42.76% in year-to-date performance and have moved -12.12% in past 5-day. Tscan Therapeutics Inc (NASDAQ:TCRX) showed a performance of -17.54% in past 30-days. Number of shares sold short was 2.23 million shares which calculate 5.8 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a rise of 42.0% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 3. It follows that stock’s current price would drop -72.41% in reaching the projected high whereas dropping to the targeted low would mean a loss of -72.41% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -14.41% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -14.36% while estimates for its earnings growth in next 5 years are of 7.58%.
Tscan Therapeutics Inc (NASDAQ:TCRX)’s Major holders
Insiders are in possession of 0.82% of company’s total shares while institution are holding 90.59 percent of that, with stock having share float percentage of 91.34%. Investors also watch the number of corporate investors in a company very closely, which is 90.59% institutions for Tscan Therapeutics Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at TCRX for having 4.46 million shares of worth $26.1 million. And as of 2024-06-30, it was holding 4.7034 of the company’s outstanding shares.
The second largest institutional holder is LYNX1 CAPITAL MANAGEMENT LP, which was holding about 5.22 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.6062 of outstanding shares, having a total worth of $30.56 million.
On the other hand, Vanguard Total Stock Market Index Fund and Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.37 shares of worth $2.38 million or 2.62% of the total outstanding shares. The later fund manager was in possession of 1.05 shares on Dec 31, 2024 , making its stake of worth around $1.82 million in the company or a holder of 2.00% of company’s stock.
